keyword
MENU ▼
Read by QxMD icon Read
search

irinotecan

keyword
https://www.readbyqxmd.com/read/28904173/impact-of-metastasectomy-in-the-multimodality-approach-for-braf-v600e-metastatic-colorectal-cancer-the-mayo-clinic-experience
#1
Benny Johnson, Zhaohui Jin, Mark J Truty, Rory L Smoot, David M Nagorney, Michael L Kendrick, Benjamin R Kipp, Axel Grothey
BACKGROUND: BRAF V600E mutations are present in 8%-10% of patients with metastatic colorectal cancer (mCRC) and portend poor prognosis. This study investigated the impact of metastasectomy for patients with BRAF V600E mCRC. Subjects, Materials, and Methods . Using prospective clinical and molecular data, patients with BRAF V600E mCRC were analyzed for clinical characteristics and survival. Statistical analyses utilized the Kaplan-Meier method, log-rank test, and Cox proportional hazard models...
September 13, 2017: Oncologist
https://www.readbyqxmd.com/read/28894577/effects-of-neoadjuvant-chemotherapy-on-patients-with-primary-vaginal-squamous-cell-carcinoma
#2
Yuchao Diao, Jinwen Jiao, Kejuan Song, Lei Wang, Teng Lv, Shuzhen Dai, Qin Yao
Vaginal cancer is a rare gynecological malignancy, mainly treated by radiotherapy and surgery. However, the effect of neoadjuvant chemotherapy on patients with vaginal cancer has not been extensively evaluated. The aim of the present study was to assess the feasibility and efficacy of irinotecan and cisplatin in the management of patients with vaginal squamous cell cancer (SCC). Two patients with International Federation of Obstetrics and Gynecology (FIGO) stage I and one patient with FIGO stage II vaginal SCC were treated with irinotecan (240 mg) and cisplatin (100 mg) every 3-4 weeks...
September 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28892430/characterization-of-pulmonary-metastases-in-children-with-hepatoblastoma-treated-on-children-s-oncology-group-protocol-ahep0731-the-treatment-of-children-with-all-stages-of-hepatoblastoma-a-report-from-the-children-s-oncology-group
#3
Allison F O'Neill, Alexander J Towbin, Mark D Krailo, Caihong Xia, Yun Gao, M Beth McCarville, Rebecka L Meyers, Eugene D McGahren, Greg M Tiao, Stephen P Dunn, Max R Langham, Christopher B Weldon, Milton J Finegold, Sarangarajan Ranganathan, Wayne L Furman, Marcio Malogolowkin, Carlos Rodriguez-Galindo, Howard M Katzenstein
Purpose To determine whether the pattern of lung nodules in children with metastatic hepatoblastoma (HB) correlates with outcome. Methods Thirty-two patients with metastatic HB were enrolled on Children's Oncology Group Protocol AHEP0731 and treated with vincristine and irinotecan (VI). Responders to VI received two additional cycles of VI intermixed with six cycles of cisplatin/fluorouracil/vincristine/doxorubicin (C5VD), and nonresponders received six cycles of C5VD alone. Patients were imaged after every two cycles and at the conclusion of therapy...
September 11, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28888554/how-to-treat-pancreatic-adenocarcinoma-in-elderly-how-far-can-we-go-in-2017
#4
REVIEW
Marine Gilabert, Jean Luc Raoul, Frederique Rousseau
Pancreatic adenocarcinoma is one of the most fatal cancers that frequently affects older patients. Limited data suggest that older patients are as likely to benefit from surgery, radiation, and chemotherapy as younger patients. The only potentially curative approach for pancreatic cancer is surgery but this is only performed in less than 20% of patients considered resectable. With improvements in surgical techniques, older patients without major comorbidities show a course of disease after resection similar to that of younger patients...
September 6, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/28884391/prognostic-significance-of-surgical-margin-size-after-neoadjuvant-folfox-and-or-folfiri-for-colorectal-liver-metastases
#5
Cynthia L Miller, Martin S Taylor, Motaz Qadan, Vikram Deshpande, Steven Worthington, Robert Smalley, Chey Collura, David P Ryan, Jill N Allen, Lawrence S Blaszkowsky, Jeffrey W Clark, Janet E Murphy, Aparna R Parikh, David Berger, Kenneth K Tanabe, Keith D Lillemoe, Cristina R Ferrone
PURPOSE: Optimal margin size when resecting colorectal liver metastases (CRLM) remains unclear, particularly in the setting of perioperative chemotherapy. We evaluated the prognostic significance of margin size in patients who received neoadjuvant FOLFOX and/or FOLFIRI prior to resection of CRLM. METHODS: Clinicopathologic factors were collected for patients who underwent curative liver resections for CRLM between 4/2004-1/2016 and received neoadjuvant oxaliplatin and/or irinotecan and 5-FU (FOLFOX, FOLFIRI)...
September 7, 2017: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/28884286/combination-of-irinotecan-oxaliplatin-and-5-fluorouracil-as-a-rechallenge-regimen-for-heavily-pretreated-metastatic-colorectal-cancer-patients
#6
Gustavo Dos Santos Fernandes, Maria Ignez Braghiroli, Michelle Artioli, Ana Carolina Carvalho Rocha Paterlini, Marcela Crosara Teixeira, Brenda Pires Gumz, Daniel da Motta Girardi, Oddone F M Braghiroli, Frederico Perego Costa, Paulo M Hoff
PURPOSE: Our objective was to evaluate the benefit of re-exposing patients with refractory metastatic colorectal cancer (mCRC) to a combination of oxaliplatin, irinotecan and 5-fluorouracil treatment. METHODS: We retrospectively analysed patients with mCRC who received a combination of oxaliplatin, irinotecan and fluorouracil as a rechallenge regimen after progressing on the same drugs. Both FOLFOXIRI and FOLFIRINOX were used. Toxicity was evaluated for each treatment cycle, and survival analysis was performed using the Kaplan-Meier method...
September 8, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28881354/preoperative-capecitabine-oxaliplatin-and-irinotecan-in-resectable-gastric-or-gastroesophageal-junction-cancer-pathological-response-as-primary-endpoint-and-fdg-pet-predictions
#7
Rosa Berenato, Federica Morano, Filippo Pietrantonio, Christian Cotsoglou, Marta Caporale, Gabriele Infante, Alessandro Pellegrinelli, Alessandra Alessi, Carlo Battiston, Jorgelina Coppa, Barbara Padovano, Alessia Mennitto, Monica Niger, Giovanni Fucà, Silvia Lazzati, Giorgio Greco, Gabriele Delconte, Filippo de Braud, Vincenzo Mazzaferro, Maria Di Bartolomeo
OBJECTIVES: This phase II trial was aimed at assessing the safety and activity of capecitabine, oxaliplatin, and irinotecan (COI regimen) as a preoperative treatment for resectable gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. METHODS: Patients affected by T3-T4/N0-N+/M0 GC/GEJ cancer were treated with the COI regimen for 4 cycles followed by restaging and gastroresection with D2 lymphadenectomy. Four postoperative cycles were scheduled. The primary endpoint was pathological response rate according to Becker et al...
September 8, 2017: Oncology
https://www.readbyqxmd.com/read/28881286/synthesis-and-evaluation-of-asymmetric-curcuminoid-analogs-as-potential-anticancer-agents-that-downregulate-nf-%C3%AE%C2%BAb-activation-and-enhance-the-sensitivity-of-gastric-cancer-cell-lines-to-irinotecan-chemotherapy
#8
Peihong Qiu, Shanshan Zhang, Yangyang Zhou, Min Zhu, Yanting Kang, Dahui Chen, Jiabing Wang, Peng Zhou, Wulan Li, Qing Xu, Rong Jin, Jianzhang Wu, Guang Liang
NF-κB is a critical target for cancer treatment due to its central role in facilitating cancer progression and desensitizing cancer cells to chemotherapeutic drugs. In this study, a series of chemically modified asymmetric curcuminoid analogs named S01-S15 were synthesized and evaluated for NF-κB inhibitory activity in gastric cancer cell lines. Cell growth inhibition assays revealed that most of these analogs effectively inhibited the growth of BGC-823, SGC-7901, and MFC cells. S06 was selected for further research...
August 24, 2017: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28880238/implications-of-abcg2-expression-on-irinotecan-treatment-of-colorectal-cancer-patients-a-review
#9
REVIEW
Dorte Lisbet Nielsen, Jesper Andreas Palshof, Nils Brünner, Jan Stenvang, Birgitte Martine Viuff
BACKGROUND: One of the main chemotherapeutic drugs used on a routine basis in patients with metastatic colorectal cancer ((m)CRC) is the topoisomerase-1 inhibitor, irinotecan. However, its usefulness is limited by the pre-existing or inevitable development of resistance. The ATP-binding cassette (ABC) transporter ABCG2/breast cancer resistance protein (BRCP) through its function in xenobiotic clearance might play an important role in irinotecan resistance. With a goal to evaluate the clinical significance of ABCG2 measurements, we here review the current literature on ABCG2 in relation to irinotecan treatment in CRC patients...
September 7, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28879724/ugt1a1-gene-polymorphism-predicts-irinotecan-induced-severe-neutropenia-and-diarrhea-in-chinese-cancer-patients
#10
Hongwei Peng, Zhouping Duan, Decheng Pan, Jinhua Wen, Xiaohua Wei
BACKGROUND: Irinotecan was widely used in colon cancer and lung cancer, etc., and adverse reactions occur some times. The primary aim of this research is to investigate the association between UGT1A1 gene polymorphisms and irinotecan-related adverse effect in Chinese Han population with a novel kind of gene chip technology. METHODS: UGT1A1*6/*28 gene polymorphisms were detected by PCR and gene chip as well as sequencing. The correlation between UGT1A1 gene polymorphisms and severe delayed diarrhea or neutropenia and effect on response rate and progression-free survival were analyzed...
September 1, 2017: Clinical Laboratory
https://www.readbyqxmd.com/read/28868015/chronic-oxaliplatin-based-chemotherapy-in-a-primary-ampullary-adenocarcinoma-patient-without-significant-peripheral-neuropathy-case-report-and-literature-review
#11
Nedal Bukhari, Eric Winquist
Peripheral neuropathy is the most common dose-limiting toxicity associated with oxaliplatin. We report on a 61-year-old female patient with advanced primary ampullary adenocarcinoma who received 35 cycles of FOLFIRINOX (5-fluorouracil, irinotecan, and oxaliplatin) chemotherapy. The patient has tolerated this treatment without developing significant peripheral neuropathy.
May 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28864605/radioembolization-of-colorectal-liver-metastases-indications-technique-and-outcomes
#12
F Edward Boas, Lisa Bodei, Constantinos T Sofocleous
Liver metastases are a major cause of death from colorectal cancer. Intraarterial therapy options for colorectal liver metastases include chemoinfusion via a hepatic arterial pump or port, irinotecan-loaded drug-eluting beads, and radioembolization using (90)Y microspheres. Intraarterial therapy allows the delivery of a high dose of chemotherapy or radiation into liver tumors while minimizing the impact on liver parenchyma and avoiding systemic effects. Specificity in intraarterial therapy can be achieved both through preferential arterial flow to the tumor and through selective catheter positioning...
September 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28859058/preoperative-chemoradiation-with-capecitabine-irinotecan-and-cetuximab-in-rectal-cancer-significance-of-pre-treatment-and-post-resection-ras-mutations
#13
Simon Gollins, Nick West, David Sebag-Montefiore, Arthur Sun Myint, Mark Saunders, Shabbir Susnerwala, Phil Quirke, Sharadah Essapen, Leslie Samuel, Bruce Sizer, Jane Worlding, Katie Southward, Gemma Hemmings, Emma Tinkler-Hundal, Morag Taylor, Daniel Bottomley, Philip Chambers, Emma Lawrie, Andre Lopes, Sandy Beare
BACKGROUND: The influence of EGFR pathway mutations on cetuximab-containing rectal cancer preoperative chemoradiation (CRT) is uncertain. METHODS: In a prospective phase II trial (EXCITE), patients with magnetic resonance imaging (MRI)-defined non-metastatic rectal adenocarinoma threatening/involving the surgical resection plane received pelvic radiotherapy with concurrent capecitabine, irinotecan and cetuximab. Resection was recommended 8 weeks later. The primary endpoint was histopathologically clear (R0) resection margin...
August 31, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28859044/vincristine-irinotecan-and-bevacizumab-in-relapsed-wilms-tumor-with-diffuse-anaplasia
#14
Amalia Schiavetti, Giulia Varrasso, Paola Collini, Anna Clerico
The prognosis of relapsed Wilms tumor (WT) with diffuse anaplasia is dismal, therefore, novel therapeutic strategies need to be explored. We reported on 2 consecutive cases with relapsed anaplastic WT who presented a partial response after 2 courses of vincristine, irinotecan, and bevacizumab association. This regimen may have a role in the treatment of patients with anaplastic advanced WT.
August 30, 2017: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/28857767/extended-topoisomerase-1-inhibition-through-liposomal-irinotecan-results-in-improved-efficacy-over-topotecan-and-irinotecan-in-models-of-small-cell-lung-cancer
#15
Shannon C Leonard, Helen Lee, Daniel F Gaddy, Stephan G Klinz, Nancy Paz, Ashish V Kalra, Daryl C Drummond, Daniel C Chan, Paul A Bunn, Jonathan B Fitzgerald, Bart S Hendriks
Liposomal irinotecan (irinotecan liposome injection, nal-IRI), a liposomal formulation of irinotecan, is designed for extended circulation relative to irinotecan and for exploiting discontinuous tumor vasculature for enhanced drug delivery to tumors. Following tumor deposition, nal-IRI is taken up by phagocytic cells followed by irinotecan release and conversion to its active metabolite, SN-38. Sustained inhibition of topoisomerase 1 by extended SN-38 exposure as a result of delivery by nal-IRI is hypothesized to enable superior antitumor activity compared with traditional topoisomerase 1 inhibitors such as conventional irinotecan and topotecan...
August 28, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/28855987/blood-transfusions-and-steatohepatitis-are-independent-risk-factors-for-complications-following-liver-resection-for-colorectal-cancer-liver-metastases
#16
Marco Massani, Giovanni Capovilla, Cesare Ruffolo, Roberta Bonariol, Paola Maccatrozzo, Francesco Tuci, Giuseppe Battistella, Gian Luca Grazi, Nicolò Bassi
The aim of the present study was to evaluate the risk factors for postoperative complications following liver resection for colorectal cancer liver metastases. Patients who underwent hepatic resection for colorectal cancer liver metastases were stratified according to chemotherapy administration and body mass index (BMI) to eliminate potential confounding factors. A univariate analysis was conducted to identify potential risk factors for postoperative complications following liver resection. Variables that exhibited a potential association were evaluated by multivariable logistic regression analysis to identify those independently associated with postoperative morbidity...
October 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28854174/orthotopic-patient-derived-xenografts-of-paediatric-solid-tumours
#17
Elizabeth Stewart, Sara M Federico, Xiang Chen, Anang A Shelat, Cori Bradley, Brittney Gordon, Asa Karlstrom, Nathaniel R Twarog, Michael R Clay, Armita Bahrami, Burgess B Freeman, Beisi Xu, Xin Zhou, Jianrong Wu, Victoria Honnell, Monica Ocarz, Kaley Blankenship, Jason Dapper, Elaine R Mardis, Richard K Wilson, James Downing, Jinghui Zhang, John Easton, Alberto Pappo, Michael A Dyer
Paediatric solid tumours arise from endodermal, ectodermal, or mesodermal lineages. Although the overall survival of children with solid tumours is 75%, that of children with recurrent disease is below 30%. To capture the complexity and diversity of paediatric solid tumours and establish new models of recurrent disease, here we develop a protocol to produce orthotopic patient-derived xenografts at diagnosis, recurrence, and autopsy. Tumour specimens were received from 168 patients, and 67 orthotopic patient-derived xenografts were established for 12 types of cancer...
August 30, 2017: Nature
https://www.readbyqxmd.com/read/28853486/evaluation-of-drug-combination-for-glioblastoma-based-on-an-intestine-liver-metabolic-model-on-microchip
#18
Mingsha Jie, Sifeng Mao, Hanyang Liu, Ziyi He, Hai-Fang Li, Jin-Ming Lin
An intestine-liver-glioblastoma biomimetic system was developed to evaluate the drug combination therapy for glioblastoma. A hollow fiber (HF) was embedded into the upper layer of the microfluidic chip for culturing Caco-2 cells to mimic drug delivery as an artificial intestine. HepG2 cells cultured in the bottom chamber of the chip acted as an artificial liver for metabolizing the drugs. The dual-drug combination to glioblastoma U251 cells was evaluated based on the intestine-liver metabolic model. The drugs, irinotecan (CPT-11), temozolomide (TMZ) and cyclophosphamide (CP), were used to dynamically stimulate the cells by continuous infusion into the intestine unit...
August 30, 2017: Analyst
https://www.readbyqxmd.com/read/28838395/randomized-phase-ii-study-of-carboplatin-plus-irinotecan-versus-carboplatin-plus-amrubicin-in-patients-with-chemo-na%C3%A3-ve-extensive-stage-small-cell-lung-cancer-north-japan-lung-cancer-study-group-njlcg-0901
#19
Naoto Morikawa, Akira Inoue, Shunichi Sugawara, Makoto Maemondo, Toshiyuki Harada, Masao Harada, Yuka Fujita, Terufumi Katoh, Hiroshi Yokouchi, Hiroshi Watanabe, Kazuhiro Usui, Toshiro Suzuki, Jun Sakakibara-Konishi, Hiroki Nagai, Mariko Kanbe, Toshihiro Nukiwa
OBJECTIVE: Carboplatin-based regimens are the standard regimens for patients with extensive-stage small-cell lung cancer (ES-SCLC). However, the efficacies of these regimens are unsatisfactory. We previously identified carboplatin plus irinotecan (CI) and carboplatin plus amrubicin (CA) as promising new carboplatin-based regimens. Accordingly, we conducted a randomized phase II study to identify the appropriate regimen for future phase III trials. MATERIALS AND METHODS: Chemotherapy-naïve patients with ES-SCLC were randomly assigned to receive 4-6 cycles of carboplatin [area under the curve (AUC) 5...
September 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28837958/terminating-the-criminal-collaboration-in-pancreatic-cancer-nanoparticle-based-synergistic-therapy-for-overcoming-fibroblast-induced-drug-resistance
#20
Liying Wang, Xiangrui Liu, Quan Zhou, Meihua Sui, Zipeng Lu, Zhuxian Zhou, Jianbin Tang, Yi Miao, Min Zheng, Weilin Wang, Youqing Shen
Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a dismal overall prognosis mainly unchanged over the past decades. PDAC is generally refractory to conventional treatments, and thus novel therapies are urgently needed. Recently, accumulating evidence has indicated that human pancreatic stellate cells (PSCs) facilitate PDAC development and drug resistance through paracrine activation of hedgehog pathway. Here, we report that smart SN38 (active metabolite of irinotecan) polymeric prodrug-based nanoparticles effectively encapsulate the commercial hedgehog pathway inhibitor GDC-0449 for co-delivery...
August 2, 2017: Biomaterials
keyword
keyword
21455
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"